Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy

Business Wire October 14, 2015

Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock

Business Wire October 9, 2015

Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock

Business Wire October 6, 2015

Sarepta Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire October 5, 2015

Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher

Business Wire October 1, 2015

Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy

Business Wire October 1, 2015

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 30, 2015

Sarepta Therapeutics Announces Appointment of Jean-Paul Kress, M.D. to the Company's Board of Directors

Business Wire September 30, 2015

Sarepta Therapeutics Announces USPTO Decision in Patent Interference Case with BioMarin Pharmaceutical

Business Wire September 30, 2015

Sarepta Therapeutics Announces Corporate Update and Report on Recent Data from Phase IIb Study of Eteplirsen for Duchenne Muscular Dystrophy

Business Wire September 25, 2015

Sarepta Therapeutics to Present Company Overview at the 2015 Morgan Stanley Global Healthcare Conference

Business Wire September 10, 2015

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 31, 2015

Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping

Business Wire August 25, 2015

Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the Potential Treatment of Duchenne Muscular Dystrophy

Business Wire August 21, 2015

Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board

Business Wire August 12, 2015

Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments

Business Wire August 6, 2015

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 31, 2015

Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate Developments on August 6, 2015

Business Wire July 30, 2015

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform

Business Wire July 22, 2015

Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company

Business Wire July 1, 2015